STK11 F354L

CI-VAR-00001109Explore in graph →NP_000446.1:p.Phe354LeuNM_000455.4:c.1062C>GClinVar 7461 CIViC 2063 rs59912467

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
STK11 F354L	Everolimus + ExemestaneCombination	Predictive	B	Supports Sensitivity Response	2	submitted	EID5568 This study analyzed response to treatment of a heavily pre-treated biphenotypic breast carcinoma patient with a mutation in the gene STK11. The STK11 F354L alteration is associated with loss of hetero… (full text at CIViC) PMID 28550065 · Parachoniak et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
7461	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Peutz-Jeghers syndrome; Hereditary cancer-predisposing syndrome; Malignant tumor of breast; Breast and/or ovarian cancer; Germ cell tumor of testis; Carcinoma of pancreas; Melanoma, cutaneous malignant, susceptibility to, 1; Azoospermia	germline	37	Jun 01, 2026